Apoptosis, proliferation, and Fas (APO-I, CD95)/Fas ligand expression in medullary carcinoma of the breast

被引:0
|
作者
Yakirevich, E
Maroun, L
Cohen, O
Izhak, OB
Rennert, G
Resnick, MB
机构
[1] Lady Davis Carmel Med Ctr, Dept Pathol, IL-34362 Haifa, Israel
[2] Rambam Med Hosp, Dept Pathol, Haifa, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[4] Lady Davis Carmel Med Ctr, Dept Surg, IL-34362 Haifa, Israel
[5] Lady Davis Carmel Med Ctr, Dept Community Med & Epidemiol, IL-34362 Haifa, Israel
来源
JOURNAL OF PATHOLOGY | 2000年 / 192卷 / 02期
关键词
breast; medullary carcinoma; apoptosis; TUNEL; proliferation; PCNA; Fas; FasL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medullary carcinoma (MC) of the breast is a unique subtype of infiltrating ductal carcinoma that is characterized by a prominent lymphoid infiltrate and improved prognosis. Activated granzyme B+/CD8(+) cytotoxic T-lymphocytes (CTLs) infiltrating tumour cell nests constitute a major subset within the lymphoid infiltrate. As CTLs destroy target tumour cells by triggering apoptosis, it mould be of interest to determine whether the apoptotic rate in MC is increased. This study evaluates the extent of apoptosis in relation to Fas (APO-1, CD95)/Fas ligand (FasL) expression in MC. Fourteen cases of typical MC (TMC) and 15 cases of atypical MC (AMC) classified according to the Ridolfi criteria, as well as 19 cases of poorly differentiated infiltrating ductal carcinoma (PDC) were evaluated. The apoptotic index (AI) was assessed by the TUNEL method on paraffin-embedded tissue. Cell proliferation was evaluated immunohistochemically by PCNA staining. The level of Fas/FasL expression was determined semiquantitatively by immunohistochemistry using a four-grade scoring system. The AI was significantly increased in TMC and AMC as opposed to the PDC subgroup (2.2 +/- 0.8, 2.1 +/- 0.8, and 1.3 +/- 0.6, respectively; p < 0.05). A significant proportion (31.8 +/- 7.9% in TMC and 25.8 +/- 9.7% in AMC) of the apoptotic tumour cells within tumour nests mere in close contact with CD3(+) lymphocytes. Increased apoptosis was not accompanied by increased proliferation of tumour cells. The extent of Fas expression did not differ between the three subgroups. FasL was expressed both by tumour infiltrating lymphocytes in MC and by tumour epithelium in all three subgroups. The observation that the majority of MCs express Fas and are infiltrated by lymphocytes expressing FasL suggests that increased apoptosis in MC is mediated by Fas/FasL. However, our observation that the majority of MCs also express Fast and the fact that tumours co-expressing Fas and FasL did not show increased apoptosis suggest that there may be additional cytotoxic pathways that lead to tumour apoptosis in MC. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 50 条
  • [21] Serum elevations of soluble Fas (CD95/Apo-I) concur in deregulating T cell apoptosis during active lupus disease
    F. Silvestris
    R. C. Williams
    N. Calvani
    D. Grinello
    M. Tucci
    P. Cafforio
    F. Dammacco
    Clinical and Experimental Medicine, 2002, 2 : 13 - 27
  • [22] Fas (CD95, Apo-1) Ligand Gene Transfer
    Salah-Eddine Lamhamedi-Cherradi
    Youhai Chen
    Journal of Clinical Immunology, 2001, 21 : 24 - 29
  • [23] Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
    Bouscary, D
    DeVos, J
    Guesnu, M
    Jondeau, K
    Viguier, F
    Melle, J
    Picard, F
    Dreyfus, F
    FontenayRoupie, M
    LEUKEMIA, 1997, 11 (06) : 839 - 845
  • [24] Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) expression
    Salih, HR
    Starling, GC
    Brandl, SF
    Pelka-Fleischer, R
    Haferlach, T
    Hiddemann, W
    Kiener, PA
    Nuessler, V
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 76 - 85
  • [25] Serum elevations of soluble Fas (CD95/Apo-I) concur in deregulating T cell apoptosis during active lupus disease
    Silvestris, F
    Williams, RC
    Calvani, N
    Grinello, D
    Tucci, M
    Cafforio, P
    Dammacco, F
    CLINICAL AND EXPERIMENTAL MEDICINE, 2002, 2 (01) : 13 - 27
  • [26] Fas (CD95, Apo-1) ligand gene transfer
    Lamhamedi-Cherradi, SE
    Chen, YH
    JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (01) : 24 - 29
  • [27] Localization and expression of Fas (CD95) ligand (FasL) and Fas receptor (Fas) in the rat epididymis
    Griffin, FC
    Lowe, DA
    Lund, T
    Cameron, DF
    FASEB JOURNAL, 1997, 11 (03): : 3569 - 3569
  • [28] Regulation of apoptosis through CD95 (APO-1/FAS) receptor/ligand interaction
    Debatin, KM
    EUROPEAN JOURNAL OF CELL BIOLOGY, 1997, 72 : 40 - 40
  • [29] Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
    Peter, ME
    Krammer, PH
    CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (05) : 545 - 551
  • [30] Regulation of apoptosis through CD95 (APO-1/FAS) receptor/ligand interaction
    Debatin, KM
    IMMUNOLOGY, 1996, 89 : SR68 - SR68